Marvin Peyton, MD
Psychiatry · Oklahoma City, OKNPI 1578644803
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Axsome Therapeutics, Inc. accounts for 70.6% of it on its own, with 26 other manufacturers making up the rest. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $139.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$42K
- Boehringer Ingelheim$6K
- Neurocrine Biosciences, Inc.$3K
- Livanova USA, Inc.$2K
- Indivior Inc.$2K
- AbbVie$950
- plus $5K from 21 others
Across 691 payments — averaging $4559.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$959K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$464K
- Boehringer Ingelheim$451K
- Supernus Pharmaceuticals, Inc.$300K
- AbbVie$183K
- Merck$174K
- plus $621K from 14 others
What the payments were for
- Consulting fees$27,47446%
- Speaking & faculty fees$11,00018%
- Travel & lodging$11,10819%
- Food & beverage$9,91617%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 56 | $42,041 |
| Boehringer Ingelheim | 31 | $6,051 |
| Neurocrine Biosciences, Inc. | 17 | $2,556 |
| Livanova USA, Inc. | 12 | $1,648 |
| Indivior Inc. | 16 | $1,529 |
| AbbVie(2 entities) | 72 | $950 |
| Otsuka America Pharmaceutical, Inc. | 40 | $923 |
| Johnson & Johnson | 54 | $729 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $573 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $517 |
| Supernus Pharmaceuticals, Inc. | 15 | $488 |
| Corium, LLC | 13 | $333 |
| Teva Pharmaceuticals USA, Inc. | 13 | $286 |
| Ironshore Pharmaceuticals Inc. | 9 | $174 |
| E.r. Squibb & Sons, L.L.C. | 4 | $160 |
| Tris Pharma Inc | 7 | $107 |
| Neuronetics, Inc. | 4 | $102 |
| Lundbeck LLC | 4 | $94 |
| Janssen Scientific Affairs, LLC | 1 | $64 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $49 |
| Alkermes, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$41,200
- SUBLOCADE$1,224
- VNS Therapy$1,154
- QELBREE$146
- CAPLYTA$135
- TRINTELLIX$130
- INGREZZA$115
- VNS - Symmetry$112
- COBENFY$110
- REXULTI$109
- Azstarys$103
How this compares
$59,518 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 31 | $79,843 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,403 |
| Lisdexamfetamine Dimesylate | 19 | $3,310 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 57 | $1,665 |
| Buprenorphine Hcl | 23 | $1,365 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $1,349 |
| Clozapine | 17 | $731 |
| Vilazodone Hcl | 18 | $686 |
| Clonazepam | 55 | $187 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $167 |
| Lorazepam | 20 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $729 | $79,84331 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $517 | $9,40324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
- Ahsan KhanOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.